Theriva Biologics reported Q1 2026 results highlighting FDA alignment on the Phase 3 trial design for VCN-01, a cancer drug targeting metastatic pancreatic ductal adenocarcinoma (PDAC). New data from the Phase 2b VIRAGE trial suggest VCN-01 may work through an immune-mediated mechanism, improving survival and tumor response, especially with repeated dosing. The company plans a dosing feasibility study in Spain and is advancing a potential Phase 2/3 trial for retinoblastoma using VCN-01 with topotecan. Cash reserves stand at $14.4 million, supporting operations into Q1 2027.
Last week, large-cap stocks in sectors like technology, electric vehicles, data centers, and healthcare experienced declines due to weak earnings guidance, regulatory worries, rising bond yields, and increased competition. Notable losers included Int...
Kinetik Holdings reported a record adjusted EBITDA for Q1 2026, driven by strong midstream logistics and favorable commodity price spreads. The company maintains a well-covered 6.4% dividend yield and trades at a 6.1x price-to-cash-flow ratio, offeri...
A report by crypto market maker Keyrock reveals that 98.6% of AI agent crypto transactions between May 2025 and April 2026 were settled in the stablecoin USDC. This dominance underscores USDC's role as the preferred settlement asset in the emerging m...
Bitcoin spot demand has sharply declined to its weakest level since mid-January, signaling reduced institutional buying despite recent price rallies. Analytics from Whale Factor show that recent BTC price gains lacked strong backing from large U.S. i...
monday.com has seen its share price fall 73% over the past year due to a broader SaaS sector decline. Despite this, the company is expected to grow revenues by nearly 20% in 2026 and 16.5% in 2027, with a strong net cash balance of $1.2 billion, abou...
